Patents Assigned to MEDIGEN, INC.
  • Publication number: 20250057932
    Abstract: Compositions for protecting subjects from diseases caused by (+)SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+)SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+)SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.
    Type: Application
    Filed: November 4, 2024
    Publication date: February 20, 2025
    Applicant: Medigen, Inc.
    Inventors: Peter Pushko, Irina Tretyakova
  • Patent number: 11576965
    Abstract: Described herein, are Bovine immunodeficiency virus gag protein (“Bgag”) recombinant virus like particles (“VLPs”) including one or more different types of target pathogen proteins. Also described, are compositions including the Bgag VLPs and the methods of making and using the novel Bgag VLP.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: February 14, 2023
    Assignee: MEDIGEN, INC.
    Inventors: Peter Pushko, Irina Tretyakova
  • Publication number: 20210322535
    Abstract: Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.
    Type: Application
    Filed: June 24, 2021
    Publication date: October 21, 2021
    Applicant: Medigen, Inc.
    Inventors: Peter Pushko, Irina Tretyakova
  • Patent number: 11058759
    Abstract: Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: July 13, 2021
    Assignee: Medigen, Inc.
    Inventors: Peter Pushko, Irina Tretyakova
  • Patent number: 10653769
    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: May 19, 2020
    Assignee: MEDIGEN, INC.
    Inventors: Peter Pushko, Igor Lukashevich
  • Publication number: 20190314482
    Abstract: Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.
    Type: Application
    Filed: November 21, 2017
    Publication date: October 17, 2019
    Applicant: Medigen, Inc.
    Inventors: Peter Pushko, Irina Tretyakova
  • Patent number: 9968672
    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: May 15, 2018
    Assignee: MEDIGEN, INC.
    Inventors: Peter Pushko, Igor Lukashevich
  • Patent number: 9694065
    Abstract: Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: July 4, 2017
    Assignee: MEDIGEN, INC.
    Inventors: Peter Pushko, Irina Tretyakova, Igor Lukashevich
  • Patent number: 9101572
    Abstract: Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: August 11, 2015
    Assignee: MEDIGEN, INC.
    Inventors: Peter Pushko, Irina Tretyakova, Igor Lukashevich
  • Patent number: 8691563
    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: April 8, 2014
    Assignee: Medigen, Inc.
    Inventors: Peter Pushko, Igor Lukashevich
  • Publication number: 20130052225
    Abstract: Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Application
    Filed: January 3, 2011
    Publication date: February 28, 2013
    Applicant: MEDIGEN, INC.
    Inventors: Peter Pushko, Irina Tretyakova, Igor Lukashevich
  • Publication number: 20110243989
    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Application
    Filed: July 17, 2009
    Publication date: October 6, 2011
    Applicant: MEDIGEN, INC.
    Inventors: Peter Pushko, Igor Lukashevich